Trial Profile
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 05 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
- 05 May 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Dec 2022.
- 28 Oct 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.